This market research report was developed based off of the responses of 301 industry professionals involved in outsourcing Phase II/III projects, and the service encounters they’ve had over the last 18 months. It includes information on respondent’s outsourcing philosophies and practices, their perceptions of and experiences with CROs involved in Phase II/III trials, CRO selection criteria, and their performance analysis of 41 different CROs.
CRO attributes evaluated in this report include: Operational excellence, Therapeutic expertise, Global footprint, Project manager quality, Patient recruitment strategy, Low cost, Network of sites/investigators, and many others.
Sponsors can use this report to find out which CRO attributes drive outsourcing partner selection for Phase II/III projects among their peers and make a more educated purchase of Phase II/III services. This data will also help to pinpoint potential delivery concerns early in a sponsor-CRO relationship in order to proactively strategize on addressing potential issues.
CROs can use the report to better understand sponsors’ outsourcing preferences and practices for selecting a contract research organization for Phase II/III projects, compare their performance against their competitors, and uncover their customers’ views of their organization’s strengths and weaknesses.
The report provides a Consumer Reports-style analysis where each of the 41 CROs included in the research is evaluated across 21 service quality attributes, making this report the most comprehensive assessment of CRO service quality in the industry. These performance metrics are categorized into four groups – budget factors, delivery factors, staff characteristics, and services. From these performance evaluations, respondents indicated how well the CROs performed with respect to expectations specific to their experience working with them. For buyers of outsourced services, the report includes highly valuable information to help guide CRO selection for Phase II/III projects.
This market research report includes in-depth analysis of CROs like Accenture, Bioclinica, Chiltern, Cognizant, Covance, DCRI-Duke, Eurofins, ICON, INC Research, inVentiv Health Clinical, Medpace, PAREXEL, and more. Download the preview file for more information.